laropiprant

Known as: (-)-((3R)-4-(4-Chlorobenzyl)-7-fluoro-5-(methylsulfonyl)-1,2,3,4-tetrahydrocyclopenta(b)indol-3-yl)acetic Acid 
A prostaglandin D2 receptor (DP1) antagonist with niacin-induced vasodilation inhibiting activity. Laropiprant binds to and inhibits the activity of… (More)
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2014
Highly Cited
2014
BACKGROUND Patients with evidence of vascular disease are at increased risk for subsequent vascular events despite effective use… (More)
  • table 1
  • figure 1
  • figure 2
  • table 2
Is this relevant?
Highly Cited
2013
Highly Cited
2013
AIMS Niacin has potentially favourable effects on lipids, but its effect on cardiovascular outcomes is uncertain. HPS2-THRIVE is… (More)
Is this relevant?
2012
2012
The use of the lipid lowering agent niacin is hampered by a frequent flush response which is largely mediated by prostaglandin… (More)
Is this relevant?
2011
2011
References 1. Remuzzi G, Benigni A, Remuzzi A. Mechanisms of progression and regression of renal lesions of chronic nephropathies… (More)
  • table 1
  • figure 1
Is this relevant?
2011
2011
BACKGROUND In patients with primary hypercholesterolemia or mixed dyslipidemia, extended-release niacin/laropiprant (ERN/LRPT… (More)
  • table 2
  • figure 1
  • figure 1
  • figure 2
  • figure 2
Is this relevant?
2010
2010
OBJECTIVE To evaluate the safety profile of extended-release niacin/laropiprant (ERN/LRPT), pooling data from studies in the… (More)
  • table 1
  • table 2
  • figure 1
  • table 3
  • figure 2
Is this relevant?
Review
2009
Review
2009
▴ Extended-release (ER) niacin (nicotinic acid)/ laropiprant is a once-daily fixed-dose combination tablet that has been… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
Is this relevant?
2009
2009
Niacin has beneficial effects on a patient's lipid and lipoprotein profiles and cardiovascular risk, particularly at doses >2 g… (More)
Is this relevant?
Highly Cited
2008
Highly Cited
2008
Niacin (nicotinic acid) is not optimally used mainly because of flushing, a process mediated primarily by prostaglandin D(2… (More)
Is this relevant?
Highly Cited
2008
Highly Cited
2008
BACKGROUND Improving lipids beyond low-density lipoprotein cholesterol (LDL-C) lowering with statin monotherapy may further… (More)
  • figure 2
  • figure 1
  • table 2
  • figure 3
  • figure 5
Is this relevant?